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Abstract Atrial fibrillation (AF) is a significant problem
for the aging population and remains a major factor under-
lying stroke risk. Warfarin anticoagulation has been proven
effective for stroke prevention in AF, but can be difficult to
manage and requires frequent monitoring. The non-vitamin
K antagonist oral anticoagulants (NOACs) have been shown
to be as effective as warfarin for stroke prevention in non-
valvular AF (NVAF) and are associated with a reduced risk
of bleeding compared with warfarin. Dabigatran, ri-
varoxaban, apixaban, and edoxaban have been approved in
the USA for reducing the risk of stroke in patients with
NVAF. In this article, AF risk assessment is discussed and
NOAC phase III clinical trials for the prevention of stroke
and systemic embolic events are reviewed. Further, differ-
ences in stroke and bleeding outcomes between NOACs are
highlighted, the use of NOACs for cardioversion and special
patient populations is discussed, and management consid-
erations for patients with AF are reviewed.
Key Points
Non-vitamin K oral anticoagulants (NOACs) are as
effective as warfarin for stroke prevention in atrial
fibrillation and are associated with less intracranial
bleeding.
NOACs may provide a simpler, safer alternative to
warfarin.
1 Introduction
As the US population ages and obesity rates increase, the
incidence of atrial fibrillation (AF) is projected to reach 2.6
million cases by 2030 [1]. In the 1991 Framingham study,
individuals with AF had a five-times-greater risk of stroke,
higher than the risk conveyed by coronary heart disease
(29), hypertension (39), or cardiac failure (49) compared
with asymptomatic individuals [2]. AF is an independent
risk factor for stroke [2] that is present in approximately
10 % of patients aged 50–59 years, increasing to 45 % in
those aged C90 years [3].
Anticoagulation is recommended for patients with AF
and prior stroke or transient ischemic attack, or for those
who are at moderate risk of stroke based on sex, age,
vascular disease, diabetes, congestive heart failure, or hy-
pertension [4]. Among patients with AF deemed at mod-
erate to high risk for stroke, anticoagulation is a cost-
effective treatment for stroke prevention, and may poten-
tially reduce the substantial financial burden associated
with stroke due to healthcare costs [5, 6]; nevertheless, it
remains underused [7]. Reasons for this underuse typically
include concerns over increased risk of bleeding as well as
limitations in healthcare access, facility availability,
physician awareness, the inconvenience of monitoring in-
ternational normalized ratio (INR) levels, and patient
compliance [8, 9].
Non-vitamin K antagonist (VKA) oral anticoagulants
(NOACs) are at least as effective as warfarin for the pre-
vention of stroke in AF and are associated with sig-
nificantly decreased risks of intracranial hemorrhage [10].
Dabigatran, rivaroxaban, apixaban, and edoxaban have
been approved for reducing the risk of stroke in patients
with nonvalvular AF (NVAF) [11–14]. Current guidelines,
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published prior to the approval of edoxaban, recommend
dabigatran, rivaroxaban, apixaban, and warfarin for use in
NVAF, and further recommend NOACs for patients who
are unable to maintain a therapeutic INR on warfarin [4,
15]. Reasons for an inability to maintain a stable INR in-
clude patient non-compliance with dietary restrictions,
missed doses, and failure to routinely monitor and thus
adjust doses when needed, drug–drug interactions, and
genetic variability that can affect warfarin metabolism
[16]. While using a NOAC will not necessarily improve a
patient’s compliance with dosing, their pharmacology
limits concerns regarding drug–drug and food–drug inter-
actions and the need for routine monitoring [17]. This re-
view discusses current treatment guidelines for AF,
provides a brief overview of NOAC pharmacology and the
phase III clinical trials for the prevention of stroke and
systemic embolic events (SEE), and covers management
considerations for patients with AF.
2 Risk Stratification
The three main goals in the treatment of AF are rate con-
trol, rhythm control, and managing stroke risk. Following
confirmation of AF and determination of stroke risk, pa-
tients who require anticoagulation should be evaluated to
balance the risk of stroke with the risk of bleeding resulting
from antithrombotic therapy. Current American Heart As-
sociation/American College of Cardiology/Heart Rhythm
Society (AHA/ACC/HRS) guidelines recommend risk
stratification using the CHA2DS2-VASc (Congestive heart
failure, Hypertension, Age C75 years [doubled], Diabetes
mellitus, prior Stroke or transient ischemic attack [TIA] or
thromboembolism [doubled], Vascular disease, Age
65–74 years, Sex category) scoring system [4, 17] (Fig. 1).
CHA2DS2-VASc outperforms CHADS2 (Congestive heart
failure, Hypertension, Age C75 years, Diabetes mellitus,
prior Stroke or TIA or thromboembolism [doubled])
(Table 1) and the ATRIA (AnTicoagulation and Risk fac-
tors In Atrial fibrillation) score in determining patients for
whom there is a truly low thrombotic risk [18–20].
Based on this risk stratification, anticoagulation may be
omitted for patients who have NVAF and a CHA2DS2-
VASc score of 0 [4]. Oral anticoagulants, aspirin, or no
treatment may be considered for patients with an inter-
mediate risk of stroke (CHA2DS2-VASc score of 1) [4,
21]. Patients with NVAF and a CHA2DS2-VASc score C2
or who have had a prior stroke or TIA should receive oral
anticoagulation, based on current guideline recommen-
dations [4]. Some debate exists regarding the net benefit
of anticoagulant treatment in patients with a CHA2DS2-
VASc score of 1. Differing rates of stroke risk in patients
with AF and one additional stroke risk have been re-
ported, suggesting that further determination of critical
risk factors in various populations should be assessed [20,
22, 23].
Assessment of the 1-year risk of major bleeding in pa-
tients with AF by HAS-BLED (Hypertension, Abnormal
renal/liver function, Stroke, Bleeding history or predispo-
sition, Labile international normalized ratio, Elderly
Fig. 1 Flowchart of oral
anticoagulant use for stroke
prevention based on risk factors
[4]. aReduced doses should be
considered; safety and efficacy
not established. bRecommended
for patients with trouble
controlling INR. CHA2DS2-
VASc congestive heart failure,
hypertension, age C75 years
(doubled), diabetes mellitus,
prior stroke or TIA or
thromboembolism (doubled),
vascular disease, age
65–74 years, sex category.
INR international normalized
ratio, OAC oral anticoagulation,
TIA transient ischemic attack
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[ 65 years], Drugs/alcohol concomitantly) [24] is recom-
mended by European Heart Rhythm Association (EHRA),
and European Society of Cardiology guidelines, but not
AHA/ACC/HRS [4, 25, 26]. To calculate this score, each
named clinical characteristic present is assigned 1 point
and summed (Table 1) [24]. A HAS-BLED score C3
indicates a patient who is potentially at high risk for
bleeding events [24]. HAS-BLED demonstrates good pre-
dictive accuracy overall, with a better predictive accuracy
for patients receiving either no antithrombotic therapy or
antiplatelet therapy [24]. In initial validation studies, a
score of 1 was associated with a 0.83 % yearly incidence of
major bleeding events, whereas a score[5 was associated
with an incidence of 16.6 % per year [27]. In patients for
whom the risk for thromboembolism and bleeding are both
high, a comprehensive management approach would in-
clude assessment and modification of extrinsic factors that
impact risk. These include adequate control of hyperten-
sion (both for thromboembolism and bleeding risk), ex-
amination of alcohol intake, and the current use of drugs
that could increase risk. Furthermore, it should be noted
that in patients with AF who develop gastrointestinal (GI)
bleeding while receiving warfarin, restarting warfarin is
associated with an overall decreased risk of thromboem-
bolism and mortality without a significantly increased risk
of recurrent GI bleeding [28].
Table 1 Rate of stroke by CHADS2/CHADS2-VASc score and bleeding risk by HAS-BLED score [4, 24]
CHADS2 CHA2DS2-VASc
Congestive heart failure Congestive heart failure
Hypertension Hypertension
Age C75 years Age C75 years (doubled)
Diabetes mellitus Diabetes mellitus
Prior stroke/TIA/thromboembolism (doubled) Prior stroke/TIA/thromboembolism (doubled)





CHA2DS2-VASc score Adjusted rate
of stroke/year (%)
0 1.9 0 0
1 2.8 1 1.3
2 4.0 2 2.2
3 5.9 3 3.2
4 8.5 4 4.0
5 12.5 5 6.7









Abnormal renal and liver function (1 point each) 1 1.02
Stroke 2 1.88
Bleeding 3 3.74
Labile INRs 4 8.70
Elderly 5 12.50




INR international normalized ratio, MI myocardial infarction, N/C not calculated, PAD peripheral arterial disease, TIA transient ischemic attack
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3 Pharmacology of Non-Vitamin K Antagonist
Oral Anticoagulants (NOACs) Versus Warfarin
Warfarin is relatively inexpensive and readily available, is
partially reversible, and has well-understood interactions
with other drugs. Warfarin is broadly indicated, and is
suitable for patients with mechanical valves [4]. Despite its
proven effectiveness, there are several recognized disad-
vantages of warfarin, including a narrow therapeutic range,
drug–drug interactions that can be delayed, food–drug in-
teractions, slow dose-adjustment time, and genetic vari-
ability in the enzymes involved in its metabolism, all of
which can affect INR [16]. In addition, in order to assure
that a therapeutic INR is maintained, frequent patient
monitoring is required [4], which some patients may find
burdensome. NOACs, which directly inhibit factor Xa
(rivaroxaban, apixaban, and edoxaban) or thrombin (dabi-
gatran), were developed to address some of the disadvan-
tages of warfarin. NOACs have a predictable anticoagulant
response, making regular laboratory monitoring unneces-
sary. Anticoagulation with NOACs is achieved quickly,
reaching peak plasma concentrations 1–4 h following oral
administration, in comparison with the delayed onset of
warfarin (Table 2) [29–32]. Half-lives of NOACs are
shorter than that of warfarin, and range from 5 to 15 h [29–
32]. NOACs have fewer drug–drug and drug–food inter-
actions than warfarin. Although rivaroxaban should be
administered with food [12], the other NOACs can be ad-
ministered without regard to food.
There are disadvantages associated with NOACs.
Bleeding risks increase when NOACs are administered
with other anticoagulants, platelet inhibitors, or non-
steroidal anti-inflammatory drugs. NOACs are substrates of
the P-glycoprotein (P-gp) transporter [14, 33–36], and
many rate-controlling and anti-arrhythmic drugs interact
with P-gp [26]. In addition, the NOACs, to varying de-
grees, are substrates of cytochrome P450 (CYP) isoenzyme
3A4 [35, 37–39]. As such, co-administration of an NOAC
with P-gp inducers or inhibitors and/or CYP3A4 inducers
or inhibitors may impact exposure to the NOAC. This is
related to the degree to which the NOAC depends on P-gp
for transport or on CYP3A4 for metabolism [34, 35]. Thus,
verapamil, diltiazem, quinidine, amiodarone, and drone-
darone are associated with increased NOAC exposure, and
use of these agents may require NOAC dose reduction or
may be contraindicated [26] in patients taking NOACs. The
lack of laboratory monitoring for NOACs may also be a
negative as it is difficult to determine the level of antico-
agulation, and compliance can be assessed only by patient
feedback and refill frequency [4, 26].
4 Phase III NOAC Clinical Trials
Phase III clinical trials evaluating NOACs are compared in
Table 3. These include the RE-LY (Randomized Evalua-
tion of Long-Term Anticoagulation Therapy) [40],
ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor
Xa Inhibition Compared with Vitamin K Antagonism for
Prevention of Stroke and Embolism Trial in Atrial Fibril-
lation) [41], ARISTOTLE (Apixaban for Reduction in
Stroke and Other Thromboembolic Events in Atrial Fib-
rillation) [42], and the ENGAGE AF-TIMI 48 trial (Ef-
fective Anticoagulation with Factor Xa Next Generation in
Atrial Fibrillation-Thrombolysis in Myocardial Infarction
Study 48) [43]. All of these trials included both hemor-
rhagic and ischemic events in the primary efficacy endpoint
of stroke and SEE (Table 3).
Table 2 Non-vitamin K antagonist anti-coagulant pharmacology [11, 12, 34, 39, 44, 45]
Dabigatran Rivaroxaban Apixaban Edoxaban
Time to maximal
concentration (h)
1–3 2–4 3–4 1–2
Half-life (h) 12–17 5–9 12 10–14
Renal eliminationa
(%)
80 66 27 35
Transporters P-gp P-gp/BCRP P-gp/BCRP P-gp
Metabolized by
CYP450
No relevant effect Yes Yes No relevant effect
Potential drug
interactions







Strong dual inhibitors of
CYP3A4 and P-gp increase
blood levels; strong dual
inducers of CYP3A4 and P-gp
Potent inhibitors
of P-gp
BCRP breast cancer resistance protein, CYP3A4 cytochrome P450 isoform 3A4, P-gp P-glycoprotein
a For dabigatran, based on absorbed dose; for rivaroxaban, apixaban, and edoxaban, based on orally administered dose
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The NOAC clinical trials cannot be directly compared
due to differences in study design and enrolled populations.
Notably, RE-LY was a prospective, randomized, open-
blinded, endpoint trial, and the other three trials employed
a double-blind, double-dummy design. (Table 3). Addi-
tionally, the number of tested doses, dose frequency, and
patient criteria for their administration differed among the
four trials. RE-LY evaluated two doses of dabigatran twice
daily, ROCKET AF evaluated one daily dose of rivaroxa-
ban, ARISTOTLE evaluated one twice-daily dose of
apixaban, and ENGAGE AF evaluated two once-daily
doses of edoxaban, with dose reductions, as described
above, allowed in ROCKET AF, ARISTOTLE, and
ENGAGE AF [40–43]. RE-LY and ARISTOTLE assessed
non-inferiority and superiority in the intention-to-treat
population, ROCKET AF assessed non-inferiority in
patients who were protocol-compliant on treatment and
superiority in the on-treatment and intention-to-treat pop-
ulation, ENGAGE AF assessed non-inferiority in the
modified intention-to-treat population, comprising patients
who underwent randomization and received at least one
dose of study drug, and superiority in the intention-to-treat
population [40–43].
Each of the trials required a diagnosis of AF for inclu-
sion in the study, with the exception of ARISTOTLE,
which included both AF and atrial flutter [42]. Larger
proportions of patients with paroxysmal AF were enrolled
in RE-LY (33 %) and ENGAGE AF (25 %) compared with
ROCKET AF (18 %) and ARISTOTLE (15 %). Due to
differences in CHADS2 score inclusion criteria, patients
with higher mean CHADS2 scores were enrolled in
ROCKET AF (3.5) and ENGAGE AF (2.8) compared with
RE-LY and ARISTOLE (2.1 for both) (Table 4) [40–43].
5 Differences in the NOAC Phase III Trial
Outcomes
5.1 Rates of Stroke, Systemic Embolism,
and Myocardial Infarction
Overall, the results of the phase III trials indicate that the
ability of NOACs to prevent strokes and SEEs is compa-
rable or better than that of warfarin (Table 4). It is im-
portant to note that the percent time in therapeutic range
(TTR) on warfarin differed between the trials, but was
Table 3 Key aspects of the non-vitamin K antagonist anti-coagulant phase III clinical trials [40–43]

















18,113 2.1 2.0 64
Warfarin Dose adjusted to INR 2.0–3.0
ROCKET AF
Rivaroxaban 20 mg od, 15 mg daily




14,264 3.5 1.9 55
Warfarin Dose adjusted to INR 2.0–3.0
ARISTOTLE
Apixaban 5 mg bid; 2.5 mg bid in pts with C2 of the
following: age C80 years, body
weight B60 kg, or serum creatinine




18,201 2.1 1.8 62
Warfarin Dose adjusted to INR 2.0–3.0
ENGAGE AF
Edoxaban 60 or 30 mg od; 50 % dose reduction for pts with
a ClCr 30–50 ml/min, body weight B60 kg, or




21,105 2.8 2.8 65
Warfarin Dose adjusted to INR 2.0–3.0
bid twice daily, CI confidence interval, ClCr creatinine clearance, CRNM clinically relevant non-major, INR international normalized ratio, od
once daily, P-gp P-glycoprotein, pts patients, TTR time in therapeutic range
a In ROCKET AF, INRs calculated 7 days after randomization and during treatment interruptions were excluded from calculation


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































higher than a reported mean US-based ‘‘real-world’’ TTR
of 53.7 % [46], for all clinical trials with the exception of
ROCKET, and the highest mean TTR was achieved in the
ENGAGE AF trial (Table 3). Rates of ischemic stroke
were similar in trials for rivaroxaban and apixaban relative
to warfarin; dabigatran 150 mg was associated with a
lower rate of ischemic stroke relative to warfarin, although
the 110-mg dose resulted in a similar rate relative to war-
farin [40–42]. Rates of ischemic stroke were similar to
those for warfarin for the high-dose edoxaban regimen, but
more frequent with the low-dose edoxaban regimen [43].
Each NOAC provided significantly greater reductions in
the risk for intracranial bleeding compared with warfarin.
In ROCKET AF, patients with a history of myocardial
infarction (MI) tended to have worse cardiovascular and
bleeding outcomes than patients without a history of MI
[47]. Rates of intracranial hemorrhage (ICH) and fatal
bleeding associated with rivaroxaban use were lower
compared with warfarin in both patients with and without a
history of prior MI [47]. Rates of MI were not significantly
different between patients treated with apixaban and war-
farin [42] or in patients treated with edoxaban compared
with warfarin [43]. Although rates of MI were initially
reported as significantly increased by dabigatran [40], this
trend has not persisted in later analyses, in which the MI
rate was similar to that with warfarin [48].
5.2 Bleeding Rates
Overall, the results of the phase III trials indicate that rates
of major bleeding or major bleeding and clinically relevant
non-major (CRNM) bleeding with NOACs are comparable
or better than with warfarin (Table 4). Rates of major
bleeding were similar between dabigatran 150 mg and
warfarin, although rates of major bleeding were sig-
nificantly reduced with dabigatran 110 mg [40]. Likewise,
rates of the composite of major bleeding and CRNM
bleeding were similar between rivaroxaban and warfarin
[41]. Rates of major bleeding were significantly reduced
relative to warfarin for apixaban and both dosing regimens
of edoxaban [42, 43].
Approximately 10 % of all cases of ICH occur in pa-
tients receiving warfarin [49]. Warfarin is associated with a
reduced risk of thromboembolism compared with no ther-
apy, and a 31 % reduction in all-cause mortality, but in-
creases the risk of ICH twofold [50]. The NOACs perform
significantly better than warfarin in reducing intracranial
bleeding risks. In each NOAC phase III trial, intracranial
bleeding rates were significantly decreased relative to
warfarin for all drugs and doses [40–43] (Table 4). Com-
pared with warfarin, apixaban reduces the risk of a first
major hemorrhage by 31 % and is associated with fewer
ICHs, fewer trauma-associated hemorrhages, and a 50 %
reduction in major hemorrhage leading to death within
30 days of the event [51]. In a subanalysis of RE-LY, 154
ICHs occurred in 153 patients, with an overall 30-day
mortality rate of 36 %. Patients who suffered an ICH
tended to be older, with a history of stroke or TIA, more
likely to have taken aspirin, less likely to have heart failure,
and more likely to have a lower estimated creatinine
clearance (ClCr) [52]. Lower rates of ICH, fatal ICH, and
subdural hematoma were noted in the patients receiving
dabigatran compared with warfarin [52]. Both the higher-
and lower-dose once-daily edoxaban regimens are associ-
ated with significant reductions in various subtypes of in-
tracranial bleeding compared with warfarin [53]. Fewer
numbers of ICHs are projected to result in fewer clinical
events, reduced stroke severity, and lower treatment and
follow-up-related costs for patients treated with NOACs
[54].
In general, the NOACs are associated with an increased
risk for GI bleeding; however, the risk varies across drugs
[10]. Dabigatran 150 mg is associated with higher rates of
GI bleeding than warfarin, whereas GI bleeding rates for
dabigatran 110 mg do not significantly differ from warfarin
[40]. This latter dose has not been approved in the USA,
but has been approved for use in Canada and the EU [55,
56]. Although there have been many postmarketing reports
of serious and fatal bleeding events associated with dabi-
gatran, bleeding rates associated with dabigatran do not
appear to be higher than those associated with warfarin
based on an analysis of insurance-claim data and admin-
istrative data from the US FDA Mini-Sentinel Database
[57]. However, other analyses confirm greater rates of GI
bleeding associated with dabigatran [58]. GI bleeding rates
are increased for rivaroxaban compared with warfarin [41].
Apixaban has not been shown to have significantly dif-
ferent GI bleeding rates compared with warfarin [42].
High-dose edoxaban results in more frequent GI bleeds
than warfarin; however, low-dose edoxaban results in
fewer GI bleeds relative to warfarin (Table 4) [10].
6 Additional Analyses
6.1 Clopidogrel/Aspirin
In AVERROES (Apixaban vs. Acetylsalicylic Acid to
Prevent Stroke in Atrial Fibrillation Patients who have
Failed or are Unsuitable for Vitamin K Antagonist Treat-
ment), apixaban was superior to aspirin for stroke pre-
vention and carried a similar bleeding risk. Roughly 1 year
after treatment, fewer patients who received apixaban than
patients who received aspirin were hospitalized for car-
diovascular reasons [59]. This reduction was driven pri-
marily by fewer stroke-related hospitalizations.
NOACs: New Choices for the Management of AF 329
In a subanalysis of RE-LY examining concomitant an-
tiplatelet use and dabigatran or warfarin use, the risks of
major bleeding were higher for patients receiving dual
antiplatelet therapy than only a single antiplatelet
medication [60]. The efficacy and safety of dabigatran was
similar for patients receiving antiplatelet therapy with
dabigatran compared with patients receiving dabigatran
only. However, this subanalysis was not statistically pow-
ered for comparisons, and more studies of these interac-
tions would be beneficial. The efficacy and safety of
apixaban was not different between patients with or with-
out concomitant aspirin use in the ARISTOTLE trial [61].
In a subanalysis of ENGAGE AF, both low- and high-dose
edoxaban regimens had similar efficacy but significantly
reduced major bleeding compared with warfarin in patients
receiving concomitant antiplatelet medication [62].
6.2 NOACs and Cardioversion/Ablation
Thromboembolic risk around the time of cardioversion can
be reduced by appropriate anticoagulation management [4].
As warfarin has a delayed onset of action, patients may
require bridging therapy with heparin or low-molecular-
weight heparin (LMWH) if a therapeutic INR range is not
achieved or if a patient is new to VKA. On the other hand,
due to their rapid onset, the use of NOACs may potentially
be advantageous for this procedure.
Most studies examining cardioversion and NOAC use
have been small and generally have not been sufficiently
powered for statistical analysis. Patients undergoing elec-
trical cardioversion, pharmacologic cardioversion, or
catheter ablation who received continuous rivaroxaban
treatment had similar numbers of incidents of stroke or
systemic embolism and similar rates of major or CRNM
bleeding compared with patients treated with warfarin
during cardioversion [63]. In a prospective, randomized
clinical trial of patients undergoing cardioversion, similar
rates of the composite of stroke, TIA, peripheral embolism,
MI, and cardiovascular death and major bleeding were
associated with rivaroxaban and warfarin, as well as similar
rates of major bleeding [64]. Rivaroxaban was also asso-
ciated with a significantly shorter time to cardioversion
than was warfarin [64]. Clinical events occurring after
cardioversion for AF were comparable in patients who had
received apixaban and warfarin at randomization; event
rates were small and did not differ for patients receiving
continuous administration of study drug [65]. Among pa-
tients undergoing cardioversion receiving dabigatran
110 mg, dabigatran 150 mg, or warfarin, rates of stroke
and SEE within 30 days of the procedure were low [66].
Some studies have shown increases in thromboembolic
complications including stroke and TIA following peri-
procedural use of dabigatran for AF ablation, yet other
studies have not shown any increase in risk [67, 68]. Ad-
ditional studies on the use of NOACs for cardioversion and
ablation are ongoing.
6.3 Atrial Fibrillation and Transient Ischemic
Attack/Heart Failure
Only a few subanalyses have examined the use of NOACs
for stroke prevention in AF patients with heart failure or
prior TIA. Apixaban had efficacy and safety superior to
that of warfarin for patients with AF and left ventricular
systolic dysfunction and heart failure-preserved ejection
fraction, with the greatest absolute benefits in the highest
risk patients with left ventricular systolic dysfunction [69].
No differences in treatment-related outcomes were shown
between patients with previous stroke or TIA for dabiga-
tran compared with warfarin, with the exception of vas-
cular death [70]. Dabigatran, rivaroxaban, and edoxaban
have shown consistent effects relative to warfarin for pa-
tients with heart failure compared with patients without
heart failure [71, 72].
7 Patient Management
Transitions between NOACs should be managed in ac-
cordance with label instructions, individual patient char-
acteristics, and the half-life and speed of onset of each
NOAC [73]. When transitioning from a NOAC to warfarin,
treatment with warfarin should be overlapped with the
NOAC to allow effective levels of anticoagulation to be
reached [25], with INR monitored until a stable level of
2–3 has been achieved [26]. Initiation of warfarin treatment
requires daily checks until a therapeutic range of 2.0–3.0
has been reached and sustained for 2 consecutive days.
When switching from warfarin to an NOAC, the INR
should be adjusted to an INR\2 for patients who will
receive dabigatran or apixaban, B2.5 for patients who will
receive edoxaban, or\3 for patients who will receive ri-
varoxaban prior to NOAC administration, to prevent ex-
cessive anticoagulation [11–14].
Boxed warnings have been issued for dabigatran, apix-
aban, edoxaban, and rivaroxaban due to an increased risk
of thromboembolic events following treatment discon-
tinuation [11–14]. Continued anticoagulation is recom-
mended for these patients unless pathological bleeding
prompted discontinuation; coverage with another antico-
agulant should be provided if patients discontinue for
reasons other than pathological bleeding [11–14].
Since the NOACs have short half-lives, it is important
that patients are properly educated regarding their use, as
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missing a dose could negatively affect anticoagulation.
Cessation of anticoagulant therapy has been associated
with high rates of stroke, SEE, and all thrombotic events
[74]. These concerns highlight the importance of education
for all patients taking anticoagulants.
7.1 Peri-Procedural Management
Recommendations call for discontinuation of warfarin
therapy 5 days prior to surgery for elective procedures
[75]. Patients with AF at a high risk of thromboembolism
should be given bridging therapy with heparin [75]. The
majority of interventions do not require bridging with
LMWH [4, 26]. NOACs can be discontinued 24 and 48 h
before procedures associated with risk of minor and major
bleeding, respectively [4, 26]. Apixaban or rivaroxaban
should be discontinued 36 h prior to low-risk procedures
for patients with kidney dysfunction (ClCr 15–30 ml/min)
[26]. The time necessary for dabigatran discontinuation
prior to procedures is graded by renal function, with longer
times recommended prior to procedures for patients with
greater degrees of renal impairment [26]. Therapy with
NOACs can be reinitiated following surgery once effective
hemostasis is achieved. Interventions to stabilize patients
who are hemodynamically unstable and require emergency
cardioversion should not be delayed due to initiation of
anticoagulation [4].
7.2 Management of Bleeding
No quantitative tests of anticoagulation exist for the
NOACs; however, qualitative levels of NOAC antico-
agulation can be assessed if the time of last dose of anti-
coagulant is known. The decision to discontinue or reverse
anticoagulation should be made in consideration of the
time sensitivity of the clinical situation [73]. Reversal of
warfarin can be achieved with administration of vitamin K,
fresh frozen plasma, or coagulation factors [76]. Currently,
the NOACs lack specific reversal agents. Prothrombin
complex concentrate (PCC) infusion reverts thrombin
generation-endogenous thrombin potential to near baseline
values and reverses rivaroxaban-induced increased pro-
thrombin time [77, 78]. PCC infusion also reverses the
effects of edoxaban on endogenous thrombin potential, but
not prothrombin time [79, 80]. The use of activated PCC,
factor VIII inhibitor bypassing activity, and an active re-
combinant form of factor VII [78, 81, 82] have also been
assessed as reversal agents; however, these drugs were
developed as hemostatic agents for bleeding and bleeding
deficiencies, not for reversal of direct FXa or IIa inhibition
[83, 84]. The synthetic small-molecule PER977 [85, 86],
catalytically inactive human recombinant FXa andex-
anet alfa (PRT064445) [87], and an antibody fragment
specific to dabigatran [88] are also under investigation as
specific reversal agents.
A total of 87–95 % of rivaroxaban and apixaban bind
plasma proteins, 35 % of dabigatran, and 40–59 % of
edoxaban is protein bound [12, 14, 31, 89]. The low protein
binding of dabigatran allows it to be removed by dialysis,
as recommended by the package insert, although this may
not be feasible in unstable patients. Dialysis is not effective




Consideration of renal function is important prior to ini-
tiation of NOAC treatment. Although the renal clearance
of NOACs vary, patients with renal impairment may re-
quire dose reduction to avoid increased plasma concen-
trations of NOACs [4, 90–92]. Of the NOACs, dabigatran
is the most dependent on renal function, with[80 % of
the dabigatran dose that is absorbed excreted in urine [37].
Rivaroxaban, edoxaban, and apixaban have less renal
dependence, and are excreted via urine by 66, 50, and
27 %, respectively [12–14]. AF patients with mild or
moderate renal impairment (ClCr 30–49 ml/min) may re-
ceive dabigatran 150 mg twice daily [11]. A reduced dose
of 75 mg twice daily is recommended for patients with a
ClCr 15–30 ml/min [11]; however, these patients were not
included in the randomized clinical trial. Rivaroxaban is
not recommended in patients with a ClCr\15 ml/min, and
renal function should be monitored in all patients receiv-
ing the drug. Patients who have any two of age C80 years,
body weight B60 kg, or elevated serum creatinine
(C1.5 mg/dl) should receive an adjusted dose of apixaban
2.5 mg twice daily [14]. Edoxaban doses should be re-
duced to 30 mg once daily in patients with a ClCr
15–50 ml/min [13]. Edoxaban should not be used in pa-
tients with a ClCr[95 ml/min [13].
Generally, bleeding rates with NOACs are similar or
reduced relative to warfarin in patients with renal impair-
ment. Major bleeding rates for dabigatran 110 and 150 mg
were similar to warfarin in this patient group [93]. Patients
with ClCr B50 ml/min receiving apixaban had more sig-
nificant reductions in major bleeding than those with higher
ClCr, even after adjusting for patients who received a re-
duced dose of 2.5 mg twice daily [94]. Less critical organ
bleeding and fatal bleeding occurred with rivaroxaban
15 mg compared with warfarin in patients with ClCr
30–49 ml/min [95, 96]. In a prespecified post hoc analysis
of ENGAGE AF, patients with a ClCr 30–50 ml/min ex-
perienced fewer adjudicated major bleeding events com-
pared with warfarin [13].
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7.3.2 Aged Patients
Hemorrhage risk increases with prior stroke and GI
bleeding, hypertension, concomitant use of antiplatelet
medication, anemia, renal insufficiency, the presence of
cerebrovascular disease, and malignancy, all of which
may be more common in the elderly [97]. Further,
elderly patients are more likely to take multiple
medications and may not receive sufficient patient
education. However, advanced age should not be seen as
a contraindication to oral anticoagulant treatment [98].
Warfarin significantly reduces stroke risk in the elderly,
and reduces the risk of ischemic stroke compared with
aspirin [97]; however, the risk of major hemorrhage in-
creases with age [99].
In general, the NOACs demonstrated similar efficacy
and safety in patients aged C75 compared with those
aged\75 years [10]. Rates of stroke or SEE are reduced
relative to warfarin and are associated with a lower risk of
bleeding in phase III trials [41–43]. Older age also had no
impact on the efficacy or safety of edoxaban, rivaroxaban,
or apixaban compared with younger patients [41–43].
Rates of stroke for patients aged C75 years compared with
younger patients were not reported for dabigatran; how-
ever, dabigatran showed a significant interaction of age by
treatment, with both dabigatran 110 mg and dabigatran
150 mg producing a higher risk of major bleeding in pa-
tients aged C75 years compared with those aged\75 years
[100]. Compared with warfarin, edoxaban decreased the
absolute risk of major bleeding, including ICH, in elderly
patients [101].
7.4 Dosing Recommendations with Certain
Concomitant Medications
Both rivaroxaban and apixaban are metabolized via
CYP3A4 [12, 14]. Dabigatran is not a CYP3A4 substrate
[37], and the metabolites of edoxaban generated by
CYP3A4 activity account for\5 % of edoxaban exposure
[13]. Due to these considerations, apixaban should be given
at a reduced dose or concomitant use should be avoided in
patients who are also taking strong P-gp and CYP3A4 in-
hibitors [14]. Dabigatran should be given at a reduced dose
to patients with moderate renal impairment who are taking
P-gp inhibitors [11], and rivaroxaban should not be ad-
ministered to patients taking combined P-gp and strong
inducers and inhibitors of CYP3A4 [12]. No edoxaban dose
reductions are required for concomitant P-gp inhibitor use
or CYP3A4 in patients with NVAF [13]. The concomitant
use of edoxaban with rifampin, a strong P-gp inducer,
should be avoided [13].
8 Conclusions
In clinical trials, NOACs have demonstrated comparable or
better risk reductions for stroke and SEE and for bleeding
compared with warfarin. In particular, they all significantly
reduce the risk for ICH. Patients treated with NOACs are
projected to have fewer clinical events and reduced stroke
severity, primarily due to fewer numbers of ICHs. Further,
the use of NOACs provides more options for specific pa-
tient groups, depending on their characteristics and con-
comitant medications. The risk of GI bleeding should be
taken under consideration for patients receiving NOACs;
however, some patient populations may benefit greatly
from the use of NOACs over traditional warfarin therapy.
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